Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uterine Neoplasms | 12 | 2023 | 225 | 5.640 |
Why?
|
Ovarian Neoplasms | 12 | 2023 | 738 | 4.060 |
Why?
|
Sex Cord-Gonadal Stromal Tumors | 6 | 2023 | 18 | 3.520 |
Why?
|
Endometrial Neoplasms | 6 | 2023 | 191 | 2.970 |
Why?
|
Carcinoma, Endometrioid | 5 | 2023 | 43 | 2.680 |
Why?
|
Biomarkers, Tumor | 13 | 2022 | 1461 | 2.680 |
Why?
|
Perivascular Epithelioid Cell Neoplasms | 3 | 2021 | 9 | 2.260 |
Why?
|
Immunohistochemistry | 14 | 2021 | 1752 | 2.070 |
Why?
|
DNA Mismatch Repair | 4 | 2023 | 52 | 1.660 |
Why?
|
Genital Neoplasms, Female | 3 | 2022 | 107 | 1.620 |
Why?
|
Neoplasms, Muscle Tissue | 2 | 2021 | 11 | 1.590 |
Why?
|
Adenocarcinoma, Clear Cell | 4 | 2022 | 62 | 1.590 |
Why?
|
Myofibroma | 2 | 2020 | 3 | 1.410 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2022 | 42 | 1.360 |
Why?
|
Adenoma | 2 | 2022 | 234 | 1.350 |
Why?
|
Adnexal Diseases | 2 | 2019 | 17 | 1.230 |
Why?
|
Carcinoma | 3 | 2022 | 434 | 1.200 |
Why?
|
Female | 42 | 2023 | 44405 | 1.190 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 3 | 2021 | 54 | 1.160 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 2 | 2016 | 22 | 1.100 |
Why?
|
Sarcoma, Endometrial Stromal | 2 | 2023 | 8 | 1.090 |
Why?
|
Rhabdomyosarcoma, Embryonal | 2 | 2022 | 6 | 1.030 |
Why?
|
Teratoma | 2 | 2023 | 50 | 1.020 |
Why?
|
Endometrial Stromal Tumors | 2 | 2023 | 4 | 1.010 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 47 | 1.010 |
Why?
|
Nuclear Receptor Coactivator 2 | 2 | 2021 | 15 | 0.980 |
Why?
|
Adenocarcinoma | 2 | 2022 | 1160 | 0.910 |
Why?
|
Leiomyoma | 2 | 2017 | 189 | 0.900 |
Why?
|
Broad Ligament | 1 | 2022 | 1 | 0.880 |
Why?
|
Neoplasms, Adnexal and Skin Appendage | 1 | 2022 | 2 | 0.870 |
Why?
|
Ribonuclease III | 2 | 2022 | 14 | 0.860 |
Why?
|
Leiomyosarcoma | 1 | 2022 | 40 | 0.840 |
Why?
|
DEAD-box RNA Helicases | 2 | 2022 | 62 | 0.830 |
Why?
|
Humans | 43 | 2023 | 86281 | 0.820 |
Why?
|
Middle Aged | 23 | 2022 | 24957 | 0.820 |
Why?
|
Krukenberg Tumor | 2 | 2018 | 3 | 0.820 |
Why?
|
Smooth Muscle Tumor | 1 | 2021 | 4 | 0.810 |
Why?
|
Adult | 21 | 2022 | 25577 | 0.790 |
Why?
|
Fibronectins | 1 | 2021 | 93 | 0.780 |
Why?
|
Angiofibroma | 1 | 2020 | 4 | 0.770 |
Why?
|
Vulvar Neoplasms | 1 | 2020 | 20 | 0.770 |
Why?
|
Glioma | 1 | 2023 | 285 | 0.760 |
Why?
|
Myxoma | 1 | 2020 | 28 | 0.760 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2018 | 348 | 0.760 |
Why?
|
Polyps | 1 | 2020 | 28 | 0.750 |
Why?
|
DNA-Binding Proteins | 5 | 2023 | 1208 | 0.750 |
Why?
|
MutS Homolog 2 Protein | 2 | 2019 | 30 | 0.740 |
Why?
|
Adnexa Uteri | 1 | 2019 | 12 | 0.720 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 302 | 0.720 |
Why?
|
Soft Tissue Neoplasms | 1 | 2020 | 126 | 0.710 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2019 | 69 | 0.690 |
Why?
|
Carcinoma, Signet Ring Cell | 1 | 2018 | 8 | 0.680 |
Why?
|
Epithelioid Cells | 1 | 2018 | 13 | 0.670 |
Why?
|
Aged | 15 | 2022 | 18353 | 0.650 |
Why?
|
Proto-Oncogene Proteins | 1 | 2021 | 645 | 0.620 |
Why?
|
Fumarate Hydratase | 1 | 2017 | 6 | 0.620 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2018 | 156 | 0.600 |
Why?
|
Breast Neoplasms | 2 | 2022 | 2881 | 0.580 |
Why?
|
Progestins | 1 | 2016 | 22 | 0.570 |
Why?
|
DNA Repair Enzymes | 1 | 2016 | 52 | 0.560 |
Why?
|
Nuclear Proteins | 2 | 2021 | 694 | 0.550 |
Why?
|
Ovary | 2 | 2021 | 250 | 0.540 |
Why?
|
Giant Cell Tumors | 1 | 2015 | 3 | 0.540 |
Why?
|
MutL Protein Homolog 1 | 3 | 2023 | 33 | 0.540 |
Why?
|
Mismatch Repair Endonuclease PMS2 | 3 | 2023 | 23 | 0.540 |
Why?
|
Diagnosis, Differential | 7 | 2022 | 1562 | 0.540 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2015 | 28 | 0.530 |
Why?
|
Ataxia Telangiectasia | 1 | 2015 | 11 | 0.530 |
Why?
|
Adenosine Triphosphatases | 1 | 2016 | 153 | 0.530 |
Why?
|
Premenopause | 1 | 2015 | 54 | 0.520 |
Why?
|
Parotid Gland | 1 | 2015 | 31 | 0.520 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2015 | 50 | 0.510 |
Why?
|
Postmenopause | 1 | 2015 | 98 | 0.500 |
Why?
|
Herpesvirus 4, Human | 1 | 2015 | 114 | 0.500 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2016 | 302 | 0.490 |
Why?
|
Testosterone | 1 | 2015 | 268 | 0.480 |
Why?
|
Skin Diseases | 1 | 2015 | 166 | 0.480 |
Why?
|
Prognosis | 8 | 2022 | 3669 | 0.470 |
Why?
|
Neoplasm Grading | 1 | 2015 | 356 | 0.460 |
Why?
|
Young Adult | 6 | 2021 | 5961 | 0.410 |
Why?
|
Aged, 80 and over | 5 | 2021 | 6481 | 0.370 |
Why?
|
Urethral Stricture | 2 | 2019 | 11 | 0.360 |
Why?
|
Gene Fusion | 2 | 2020 | 38 | 0.360 |
Why?
|
Mutation | 4 | 2021 | 3952 | 0.350 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2022 | 274 | 0.350 |
Why?
|
Gene Rearrangement | 2 | 2020 | 170 | 0.320 |
Why?
|
Papillomavirus Infections | 2 | 2022 | 239 | 0.280 |
Why?
|
Adolescent | 4 | 2021 | 8968 | 0.280 |
Why?
|
Biopsy | 3 | 2019 | 1160 | 0.280 |
Why?
|
Child | 3 | 2023 | 6913 | 0.260 |
Why?
|
Cervix Uteri | 3 | 2022 | 64 | 0.250 |
Why?
|
Oncogene Fusion | 2 | 2021 | 8 | 0.250 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 1671 | 0.250 |
Why?
|
Tissue Array Analysis | 2 | 2021 | 124 | 0.240 |
Why?
|
Necrosis | 1 | 2023 | 204 | 0.230 |
Why?
|
Kaplan-Meier Estimate | 2 | 2016 | 859 | 0.230 |
Why?
|
Lichen Sclerosus et Atrophicus | 2 | 2019 | 7 | 0.230 |
Why?
|
Incidence | 2 | 2019 | 1568 | 0.230 |
Why?
|
Adenosarcoma | 1 | 2022 | 3 | 0.220 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2022 | 18 | 0.220 |
Why?
|
Wolffian Ducts | 1 | 2022 | 7 | 0.220 |
Why?
|
Phenotype | 2 | 2019 | 2375 | 0.220 |
Why?
|
Solitary Fibrous Tumors | 1 | 2022 | 5 | 0.210 |
Why?
|
Peutz-Jeghers Syndrome | 1 | 2021 | 8 | 0.210 |
Why?
|
Hemorrhage | 1 | 2023 | 265 | 0.200 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 45 | 0.200 |
Why?
|
Cystadenoma, Papillary | 1 | 2021 | 8 | 0.200 |
Why?
|
SMARCB1 Protein | 1 | 2021 | 13 | 0.200 |
Why?
|
Nuclear Receptor Coactivator 1 | 1 | 2021 | 24 | 0.200 |
Why?
|
Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2021 | 20 | 0.200 |
Why?
|
Urogenital Neoplasms | 1 | 2021 | 22 | 0.200 |
Why?
|
Neoplasms, Connective and Soft Tissue | 1 | 2020 | 4 | 0.200 |
Why?
|
Genitalia, Female | 1 | 2020 | 25 | 0.200 |
Why?
|
Vulva | 1 | 2020 | 23 | 0.190 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2021 | 128 | 0.190 |
Why?
|
DNA Helicases | 1 | 2021 | 79 | 0.190 |
Why?
|
Immunophenotyping | 1 | 2020 | 211 | 0.190 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 2267 | 0.180 |
Why?
|
Papillomaviridae | 2 | 2022 | 153 | 0.180 |
Why?
|
Urologic Surgical Procedures, Male | 1 | 2019 | 11 | 0.180 |
Why?
|
Sarcoma | 1 | 2021 | 211 | 0.170 |
Why?
|
Urethra | 1 | 2019 | 106 | 0.170 |
Why?
|
Gene Dosage | 1 | 2019 | 207 | 0.170 |
Why?
|
Pregnancy | 2 | 2016 | 2885 | 0.160 |
Why?
|
Mitosis | 1 | 2018 | 151 | 0.160 |
Why?
|
Retrospective Studies | 3 | 2023 | 8431 | 0.160 |
Why?
|
Genomics | 1 | 2023 | 710 | 0.150 |
Why?
|
Tumor Burden | 1 | 2018 | 288 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 1305 | 0.150 |
Why?
|
Carcinoma, Renal Cell | 1 | 2021 | 425 | 0.150 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2016 | 27 | 0.140 |
Why?
|
Boston | 1 | 2016 | 33 | 0.140 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2016 | 131 | 0.140 |
Why?
|
Salpingectomy | 1 | 2015 | 3 | 0.140 |
Why?
|
California | 1 | 2016 | 138 | 0.140 |
Why?
|
Penicillamine | 1 | 2015 | 12 | 0.140 |
Why?
|
Voice Disorders | 1 | 2015 | 8 | 0.140 |
Why?
|
Elastic Tissue | 1 | 2015 | 18 | 0.140 |
Why?
|
Inflammation | 1 | 2021 | 913 | 0.140 |
Why?
|
Luteinization | 1 | 2015 | 1 | 0.140 |
Why?
|
Alopecia | 1 | 2015 | 34 | 0.140 |
Why?
|
Hirsutism | 1 | 2015 | 61 | 0.140 |
Why?
|
Ovariectomy | 1 | 2015 | 81 | 0.130 |
Why?
|
Hyperplasia | 1 | 2015 | 148 | 0.130 |
Why?
|
Antirheumatic Agents | 1 | 2015 | 51 | 0.130 |
Why?
|
Scleroderma, Systemic | 1 | 2015 | 43 | 0.130 |
Why?
|
Neoplasm Staging | 2 | 2022 | 1932 | 0.130 |
Why?
|
Septum of Brain | 2 | 2005 | 2 | 0.130 |
Why?
|
Stromal Cells | 1 | 2016 | 142 | 0.130 |
Why?
|
Ovarian Diseases | 1 | 2015 | 32 | 0.130 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2015 | 16 | 0.130 |
Why?
|
Parasympathetic Nervous System | 2 | 2005 | 33 | 0.130 |
Why?
|
Fibroma | 1 | 2015 | 32 | 0.130 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 123 | 0.130 |
Why?
|
Hypoglycemia | 1 | 2015 | 106 | 0.130 |
Why?
|
Endometriosis | 1 | 2015 | 58 | 0.130 |
Why?
|
Estradiol | 1 | 2015 | 249 | 0.130 |
Why?
|
Extremities | 1 | 2015 | 165 | 0.120 |
Why?
|
Transcription Factors | 1 | 2021 | 1555 | 0.110 |
Why?
|
Pregnancy Complications | 1 | 2016 | 336 | 0.110 |
Why?
|
Reproducibility of Results | 1 | 2018 | 2699 | 0.110 |
Why?
|
Insulin | 1 | 2015 | 1159 | 0.090 |
Why?
|
Axotomy | 2 | 2005 | 8 | 0.090 |
Why?
|
Time Factors | 1 | 2016 | 5198 | 0.080 |
Why?
|
Capsid Proteins | 1 | 2005 | 32 | 0.070 |
Why?
|
Nerve Growth Factors | 1 | 2005 | 63 | 0.070 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 2434 | 0.060 |
Why?
|
Polyethyleneimine | 1 | 2004 | 7 | 0.060 |
Why?
|
Nerve Growth Factor | 1 | 2004 | 17 | 0.060 |
Why?
|
Genetic Vectors | 1 | 2005 | 438 | 0.060 |
Why?
|
Gene Transfer Techniques | 1 | 2004 | 152 | 0.060 |
Why?
|
Follow-Up Studies | 2 | 2022 | 3616 | 0.060 |
Why?
|
Male | 5 | 2021 | 40860 | 0.060 |
Why?
|
Co-Repressor Proteins | 1 | 2023 | 18 | 0.060 |
Why?
|
Biomarkers | 2 | 2019 | 1709 | 0.060 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2021 | 15 | 0.050 |
Why?
|
Uterus | 1 | 2023 | 214 | 0.050 |
Why?
|
DNA Mutational Analysis | 1 | 2022 | 526 | 0.050 |
Why?
|
beta Catenin | 1 | 2022 | 250 | 0.050 |
Why?
|
Microscopy, Electron | 1 | 2021 | 502 | 0.050 |
Why?
|
Point Mutation | 1 | 2021 | 246 | 0.050 |
Why?
|
Repressor Proteins | 1 | 2023 | 403 | 0.040 |
Why?
|
Preoperative Period | 1 | 2019 | 91 | 0.040 |
Why?
|
Sequence Analysis, DNA | 1 | 2021 | 853 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 455 | 0.040 |
Why?
|
Reoperation | 1 | 2019 | 589 | 0.040 |
Why?
|
Protein Biosynthesis | 1 | 2019 | 378 | 0.040 |
Why?
|
Papanicolaou Test | 1 | 2016 | 38 | 0.040 |
Why?
|
Recurrence | 1 | 2019 | 1137 | 0.040 |
Why?
|
Vaginal Smears | 1 | 2016 | 68 | 0.040 |
Why?
|
Neurons | 1 | 2004 | 1545 | 0.030 |
Why?
|
Vagina | 1 | 2016 | 161 | 0.030 |
Why?
|
Stereotaxic Techniques | 2 | 2005 | 69 | 0.030 |
Why?
|
Risk Assessment | 1 | 2022 | 2253 | 0.030 |
Why?
|
Green Fluorescent Proteins | 2 | 2005 | 305 | 0.030 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 1381 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 2 | 2005 | 1214 | 0.030 |
Why?
|
Prospective Studies | 1 | 2019 | 4194 | 0.020 |
Why?
|
Rats | 2 | 2005 | 3984 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2019 | 7949 | 0.020 |
Why?
|
Fornix, Brain | 1 | 2005 | 2 | 0.020 |
Why?
|
Choline O-Acetyltransferase | 1 | 2005 | 23 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2005 | 266 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 376 | 0.020 |
Why?
|
Indicators and Reagents | 1 | 2004 | 72 | 0.020 |
Why?
|
Transgenes | 1 | 2004 | 180 | 0.010 |
Why?
|
Luminescent Proteins | 1 | 2004 | 144 | 0.010 |
Why?
|
Animals | 2 | 2005 | 26518 | 0.010 |
Why?
|
Mice | 1 | 2004 | 11313 | 0.010 |
Why?
|